The temporomandibular joint (TMJ). Credit: Anatomist90 / commons.wikimedia.org.

Regenative Labs (Regenative) has announced a new independent study on the application of Wharton’s Jelly for tissue defects associated with temporomandibular disorder (TMD).

The Pain and Sleep Therapy Center, a Regenative observational study clinical site, is sponsoring the study, which has been approved by the Institutional Review Board (IRB) of the Institute of Cellular and Regenerative Medicine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The single-site, prospective cohort trial will be led by Robinson and NP Rachel Reynolds. Reynolds said: “Working with Wharton’s jelly has opened my eyes to the future for regenerative applications.

“We are so excited to have obtained IRB approval to not only help strengthen the growing body of evidence for Wharton’s jelly application but to also help the population of TMJ dysfunction sufferers who deserve more alternative interventions.”

The objective of this study is to assess the benefits of utilising Wharton’s jelly tissue allografts to address cartilage defects occurring in the temporomandibular joint (TMJ), as well as the potential impact on mastication and TMJ translation.

It will assess the safety of utilising Wharton’s jelly tissue allografts as an alternative treatment option to surgery or other invasive procedures in cases of treatment-resistant TMD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the study will also evaluate the efficacy and overall improvement of the patients in pain-related symptoms pertaining to bite force tolerance with mastication and lateral translation.

Dr Ryan Robinson said: “We are excited to be pioneers in bringing regenerative medicine into the TMJ world and create an advanced, progressive model for our patients.”